{"schema_version":"secwatch.filing_event.v1","accession":"0001285550-25-000010","form_type":"8-K","ticker":"CLPT","cik":"0001285550","company_name":"ClearPoint Neuro, Inc.","filed_at":"2025-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.583371+00:00","generated_at":"2026-05-17T14:18:49.559037+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ClearPoint Neuro Q2 revenue record $9.2M (+17% YoY); secures up to $105M note financing","bullets":["Record Q2 revenue $9.2M, up 17% YoY; neurosurgery segment revenue up 33% to $3.4M.","Operating expenses $11.2M (+16% YoY); gross margin 60% vs 63% on higher inventory reserves.","Entered $105M note financing with Oberland Capital; $30M funded at closing plus $3.5M stock purchase.","Cash and equivalents $41.5M at June 30, compared to $20.1M at year-end 2024.","Full-year 2025 revenue outlook reaffirmed at $36.0M-$41.0M."],"urls":{"canonical":"https://secwatch.observer/filing/0001285550-25-000010","json":"https://secwatch.observer/filing/0001285550-25-000010.json","markdown":"https://secwatch.observer/filing/0001285550-25-000010.md","text":"https://secwatch.observer/filing/0001285550-25-000010.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1285550/000128555025000010/0001285550-25-000010-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1285550/000128555025000010/clpt-20250812.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T14:18:49.559037+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}